Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy

Makiko Higashimoto, Masahiko Takahashi, Ritsuko Jokyu, Hidetsugu Saito

Research output: Contribution to journalArticle

Abstract

A highly sensitive second generation HCV core antigen assay has recently been developed. We compared viral disappearance and kinetics data between commercially available core antigen assays, Lumipulse Ortho HCV Ag, and a quantitative HCV RNA PCR assay, Cobas Amplicor HCV Monitor Test, Version 2 to estimate the predictive benefit of sustained viral response (SVR) and non-SVR in 59 patients treated with interferon and ribavirin combination therapy. We found a good correlation between HCV core Ag and HCV RNA level regardless of genotype. Although the sensitivity of the core antigen assay was lower than PCR, the dynamic range was broader than that of the PCR assay, so that we did not need to dilute the samples in 59 patients. We detected serial decline of core Ag levels in 24 hrs, 7 days and 14 days after interferon combination therapy. The decline of core antigen levels was significant in SVR patients compared to non-SVR as well as in genotype 2a, 2b patients compared to 1b. Core antigen-negative on day 1 could predict all 10 SVR patients (PPV = 100%), whereas RNA-negative could predict 22 SVR out of 25 on day 14 (PPV = 88.0%). None of the patients who had detectable serum core antigen on day 14 became SVR(NPV = 100%), although NPV was 91.2% on RNA negativity. An easy, simple, low cost new HCV core antigen detecting system seems to be useful for assessing and monitoring IFN treatment for HCV.

Original languageEnglish
Pages (from-to)111-115
Number of pages5
JournalRinsho byori. The Japanese journal of clinical pathology
Volume54
Issue number2
Publication statusPublished - 2006
Externally publishedYes

Fingerprint

Ribavirin
Interferons
Antigens
RNA
Polymerase Chain Reaction
Therapeutics
Genotype
Costs and Cost Analysis
Serum

Cite this

Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy. / Higashimoto, Makiko; Takahashi, Masahiko; Jokyu, Ritsuko; Saito, Hidetsugu.

In: Rinsho byori. The Japanese journal of clinical pathology, Vol. 54, No. 2, 2006, p. 111-115.

Research output: Contribution to journalArticle

@article{24d9db0e500c413aa150cfeb2ca98bad,
title = "Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy",
abstract = "A highly sensitive second generation HCV core antigen assay has recently been developed. We compared viral disappearance and kinetics data between commercially available core antigen assays, Lumipulse Ortho HCV Ag, and a quantitative HCV RNA PCR assay, Cobas Amplicor HCV Monitor Test, Version 2 to estimate the predictive benefit of sustained viral response (SVR) and non-SVR in 59 patients treated with interferon and ribavirin combination therapy. We found a good correlation between HCV core Ag and HCV RNA level regardless of genotype. Although the sensitivity of the core antigen assay was lower than PCR, the dynamic range was broader than that of the PCR assay, so that we did not need to dilute the samples in 59 patients. We detected serial decline of core Ag levels in 24 hrs, 7 days and 14 days after interferon combination therapy. The decline of core antigen levels was significant in SVR patients compared to non-SVR as well as in genotype 2a, 2b patients compared to 1b. Core antigen-negative on day 1 could predict all 10 SVR patients (PPV = 100{\%}), whereas RNA-negative could predict 22 SVR out of 25 on day 14 (PPV = 88.0{\%}). None of the patients who had detectable serum core antigen on day 14 became SVR(NPV = 100{\%}), although NPV was 91.2{\%} on RNA negativity. An easy, simple, low cost new HCV core antigen detecting system seems to be useful for assessing and monitoring IFN treatment for HCV.",
author = "Makiko Higashimoto and Masahiko Takahashi and Ritsuko Jokyu and Hidetsugu Saito",
year = "2006",
language = "English",
volume = "54",
pages = "111--115",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "2",

}

TY - JOUR

T1 - Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy

AU - Higashimoto, Makiko

AU - Takahashi, Masahiko

AU - Jokyu, Ritsuko

AU - Saito, Hidetsugu

PY - 2006

Y1 - 2006

N2 - A highly sensitive second generation HCV core antigen assay has recently been developed. We compared viral disappearance and kinetics data between commercially available core antigen assays, Lumipulse Ortho HCV Ag, and a quantitative HCV RNA PCR assay, Cobas Amplicor HCV Monitor Test, Version 2 to estimate the predictive benefit of sustained viral response (SVR) and non-SVR in 59 patients treated with interferon and ribavirin combination therapy. We found a good correlation between HCV core Ag and HCV RNA level regardless of genotype. Although the sensitivity of the core antigen assay was lower than PCR, the dynamic range was broader than that of the PCR assay, so that we did not need to dilute the samples in 59 patients. We detected serial decline of core Ag levels in 24 hrs, 7 days and 14 days after interferon combination therapy. The decline of core antigen levels was significant in SVR patients compared to non-SVR as well as in genotype 2a, 2b patients compared to 1b. Core antigen-negative on day 1 could predict all 10 SVR patients (PPV = 100%), whereas RNA-negative could predict 22 SVR out of 25 on day 14 (PPV = 88.0%). None of the patients who had detectable serum core antigen on day 14 became SVR(NPV = 100%), although NPV was 91.2% on RNA negativity. An easy, simple, low cost new HCV core antigen detecting system seems to be useful for assessing and monitoring IFN treatment for HCV.

AB - A highly sensitive second generation HCV core antigen assay has recently been developed. We compared viral disappearance and kinetics data between commercially available core antigen assays, Lumipulse Ortho HCV Ag, and a quantitative HCV RNA PCR assay, Cobas Amplicor HCV Monitor Test, Version 2 to estimate the predictive benefit of sustained viral response (SVR) and non-SVR in 59 patients treated with interferon and ribavirin combination therapy. We found a good correlation between HCV core Ag and HCV RNA level regardless of genotype. Although the sensitivity of the core antigen assay was lower than PCR, the dynamic range was broader than that of the PCR assay, so that we did not need to dilute the samples in 59 patients. We detected serial decline of core Ag levels in 24 hrs, 7 days and 14 days after interferon combination therapy. The decline of core antigen levels was significant in SVR patients compared to non-SVR as well as in genotype 2a, 2b patients compared to 1b. Core antigen-negative on day 1 could predict all 10 SVR patients (PPV = 100%), whereas RNA-negative could predict 22 SVR out of 25 on day 14 (PPV = 88.0%). None of the patients who had detectable serum core antigen on day 14 became SVR(NPV = 100%), although NPV was 91.2% on RNA negativity. An easy, simple, low cost new HCV core antigen detecting system seems to be useful for assessing and monitoring IFN treatment for HCV.

UR - http://www.scopus.com/inward/record.url?scp=33646384945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646384945&partnerID=8YFLogxK

M3 - Article

C2 - 16548229

AN - SCOPUS:33646384945

VL - 54

SP - 111

EP - 115

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 2

ER -